E.S. Barr & Co’s AbbVie ABBV Stock Holding History

E.S. Barr & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$696K	Sell	3,201 -15	-0.5%	-$3.33K	0.04%	63
2025 Q4	$735K	Buy	3,216 +137	+4%	+$31.2K	0.04%	65
2025 Q3	$713K	Sell	3,079 -75	-2%	-$15.3K	0.04%	64
2025 Q2	$585K	Sell	3,154 -209	-6%	-$38.8K	0.03%	70
2025 Q1	$705K	Sell	3,363 -176	-5%	-$34.2K	0.04%	60
2024 Q4	$629K	Sell	3,539 -26	-0.7%	-$4.78K	0.04%	64
2024 Q3	$704K	Buy	3,565 +866	+32%	+$162K	0.04%	63
2024 Q2	$463K	Buy	2,699 +10	+0.4%	+$1.66K	0.03%	67
2024 Q1	$490K	Sell	2,689 -2,391	-47%	-$412K	0.03%	63
2023 Q4	$787K	Buy	5,080 +101	+2%	+$14.7K	0.05%	57
2023 Q3	$742K	Sell	4,979 -600	-11%	-$88.1K	0.05%	55
2023 Q2	$752K	Buy	5,579 +500	+10%	+$73.3K	0.06%	56
2023 Q1	$809K	Hold	5,079	–	–	0.07%	53
2022 Q4	$821K	Sell	5,079 -72	-1%	-$11K	0.07%	55
2022 Q3	$691K	Sell	5,151 -200	-4%	-$28.7K	0.06%	57
2022 Q2	$820K	Hold	5,351	–	–	0.07%	56
2022 Q1	$867K	Hold	5,351	–	–	0.06%	60
2021 Q4	$725K	Sell	5,351 -11	-0.2%	-$1.3K	0.05%	66
2021 Q3	$578K	Buy	5,362 +11	+0.2%	+$1.26K	0.04%	67
2021 Q2	$603K	Buy	5,351 +754	+16%	+$84.9K	0.04%	64
2021 Q1	$497K	Hold	4,597	–	–	0.04%	61
2020 Q4	$493K	Hold	4,597	–	–	0.04%	59
2020 Q3	$403K	Hold	4,597	–	–	0.04%	60
2020 Q2	$451K	Hold	4,597	–	–	0.05%	57
2020 Q1	$350K	Sell	4,597 -1,952	-30%	-$166K	0.04%	63
2019 Q4	$580K	Buy	6,549 +382	+6%	+$31.7K	0.06%	57
2019 Q3	$467K	Hold	6,167	–	–	0.05%	61
2019 Q2	$448K	Sell	6,167 -550	-8%	-$43.2K	0.04%	63
2019 Q1	$541K	Buy	6,717 +550	+9%	+$45K	0.06%	59
2018 Q4	$569K	Buy	6,167 +319	+5%	+$28.1K	0.06%	59
2018 Q3	$553K	Sell	5,848 -200	-3%	-$19K	0.05%	64
2018 Q2	$560K	Hold	6,048	–	–	0.06%	65
2018 Q1	$572K	Hold	6,048	–	–	0.06%	64
2017 Q4	$585K	Sell	6,048 -61	-1%	-$5.75K	0.06%	63
2017 Q3	$543K	Buy	6,109 +370	+6%	+$28.2K	0.06%	61
2017 Q2	$416K	Buy	5,739 +113	+2%	+$7.6K	0.05%	65
2017 Q1	$367K	Buy	5,626 +322	+6%	+$20.2K	0.04%	65
2016 Q4	$332K	Buy	5,304 +193	+4%	+$11.8K	0.04%	68
2016 Q3	$322K	Hold	5,111	–	–	0.04%	66
2016 Q2	$316K	Buy	5,111 +100	+2%	+$6.09K	0.04%	69
2016 Q1	$286K	Hold	5,011	–	–	0.03%	71
2015 Q4	$297K	Hold	5,011	–	–	0.04%	72
2015 Q3	$273K	Hold	5,011	–	–	0.03%	72
2015 Q2	$337K	Hold	5,011	–	–	0.04%	66
2015 Q1	$293K	Sell	5,011 -276	-5%	-$16.7K	0.03%	69
2014 Q4	$346K	Hold	5,287	–	–	0.04%	66
2014 Q3	$305K	Hold	5,287	–	–	0.04%	72
2014 Q2	$298K	Sell	5,287 -847	-14%	-$44.4K	0.04%	75
2014 Q1	$315K	Sell	6,134 -651	-10%	-$32.9K	0.04%	72
2013 Q4	$358K	Hold	6,785	–	–	0.04%	68
2013 Q3	$303K	Buy	6,785 +834	+14%	+$37K	0.04%	67
2013 Q2	$246K	Buy	+5,951	New	+$260K	0.03%	71

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

E.S. Barr & Co's ABBV Position: Q1 2026 in Review

E.S. Barr & Co reduced its AbbVie (ABBV) stake by 0.47% in Q1 2026, selling an estimated $3.33K and leaving 3,201 shares worth $696K. The position accounts for 0.04% of the portfolio, ranked #63.

E.S. Barr & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $867K in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

E.S. Barr & Co held 3,201 shares of AbbVie worth $696K as of Q1 2026.
E.S. Barr & Co sold 15 AbbVie shares in Q1 2026, an estimated $3.33K.
AbbVie made up 0.04% of E.S. Barr & Co's portfolio in Q1 2026, its #63 holding.
E.S. Barr & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
E.S. Barr & Co's AbbVie position peaked at $867K in Q1 2022.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on E.S. Barr & Co's 13F filing for Q1 2026, filed 13 May 2026.